Catabasis Pharmaceuticals
Stage
PIPE | IPOTotal Raised
$103.49MMarket Cap
0.23BStock Price
13.72About Catabasis Pharmaceuticals
Catabasis is a clinical stage biotechnology company with a robust portfolio of investigational new medicines for the treatment of cardiovascular, metabolic and inflammatory diseases. The company's drug development programs are rooted in the principles of Pathway Pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its SMART (Safely Metabolized And Rationally Targeted) linker technology, we conjugate two drugs that act on different components of a disease pathway to produce new chemical entities with improved safety, tolerability and significantly enhanced efficacy. This approach has allowed Catabasis to move rapidly from concept to investigational new drug (IND) application, and to produce new medicines with superior efficacy.
Missing: Catabasis Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Catabasis Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Catabasis Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Catabasis Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Catabasis Pharmaceuticals Patents
Catabasis Pharmaceuticals has filed 52 patents.
The 3 most popular patent topics include:
- Rare diseases
- Glucocorticoids
- Muscular dystrophy
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/25/2015 | 4/9/2019 | Rare diseases, Fatty acids, Olfactory receptors, Cell biology, Cystic fibrosis | Grant |
Application Date | 11/25/2015 |
|---|---|
Grant Date | 4/9/2019 |
Title | |
Related Topics | Rare diseases, Fatty acids, Olfactory receptors, Cell biology, Cystic fibrosis |
Status | Grant |
Latest Catabasis Pharmaceuticals News
Jun 17, 2022
Competitive Landscape and Global Duchenne Muscular Dystrophy Market Share Analysis· Pfizer Inc, Sarepta Therapeutics · PTC Therapeutics, FibroGen Inc· F. Hoffmann-La Roche Ltd,· ITALFARMACO S. A· BioMarin, Catabasis Pharmaceuticals, Inc· ReveraGen BioPharma, Inc· Bristol-Myers Squibb Company · Novartis AG, Hikma Pharmaceuticals PLC· Endo International IncGet Full Access Of Report https://www. com/reports/global-duchenne-muscular-dystrophy-market MAJOR TOC OF THE REPORTØ INTRODUCTIONØ MARKET SEGMENTATIONØ EXECUTIVE SUMMARYØ PREMIUM INSIGHTSØ MARKET OVERVIEWØ MARKET, COMPANY LANDSCAPEØ SWOT ANALYSISØ COMPANY PROFILEØ QUESTIONNAIRERELATED REPORTSGet TOC Details https://www. comBrowse Related Reports@ Global Hollow Core Insulator Market Global Duchenne Muscular Dystrophy Market
Catabasis Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Catabasis Pharmaceuticals's headquarters?
Catabasis Pharmaceuticals's headquarters is located at One Kendall Square, Cambridge.
What is Catabasis Pharmaceuticals's latest funding round?
Catabasis Pharmaceuticals's latest funding round is PIPE.
How much did Catabasis Pharmaceuticals raise?
Catabasis Pharmaceuticals raised a total of $103.49M.
Who are the investors of Catabasis Pharmaceuticals?
Investors of Catabasis Pharmaceuticals include Perceptive Advisors, MedImmune Ventures, SV Health Investors, Clarus, Advanced Technology Ventures and 4 more.
Who are Catabasis Pharmaceuticals's competitors?
Competitors of Catabasis Pharmaceuticals include Aquinox Pharmaceuticals, Relypsa, Anacor Pharmaceuticals, Tolera Therapeutics, BioRelix and 14 more.
Compare Catabasis Pharmaceuticals to Competitors
Avidimer Therapeutics is engaged in the discovery and development of therapeutics for inflammatory diseases
is engaged in endocannabinoid research with the ability to address major unmet medical needs for selected diseases with clear competitive advantage over present therapies. The company's mission is the discovery, development and commercialization of therapeutics in the areas of neuropathic, inflammatory and somatic pain, obesity, neuroprotection, and addiction and glaucoma.
Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.
SBIO is focused on the discovery and development of small molecule oncology drugs.
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Verva Pharmaceuticals is an exciting, clinical-stage pharmaceutical company focused on the discovery and development of therapies to treat metabolic diseases (formerly Adipogen).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.